Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 136 to 150 of 257 results for radiotherapy

  1. Intensity modulated radiotherapy for breast cancer [ID16]

    Discontinued Reference number: GID-TAG390

    Technology appraisal guidance
    Discontinued

  2. Intensity modulated radiotherapy for prostate cancer [ID17]

    Discontinued Reference number: GID-TAG396

    Technology appraisal guidance
    Discontinued

  3. Further research on endoscopic carbon dioxide laser cricopharyngeal myotomy for relief of oropharyngeal dysphagia could include the publication of collaborative audit data. Reports should separate outcomes for different groups of patients; in particular for patients with primary neuromuscular dysfunction alone, those with associated phargyngeal diverticula and those with dysphagia caused by radiotherapy. Outcome measures should include dysphagia scores, quality of life, long-term outcomes and the need for further treatment. All complications should be reported. NICE may update this guidance on publication of further evidence.

    associated phargyngeal diverticula and those with dysphagia caused by radiotherapy. Outcome measures should include dysphagia scores,...

    Research recommendation
    Published
    6 April 2016

  4. Microwave ablation for primary or metastatic cancer in the lung (HTG609)

    Evidence-based recommendations on microwave ablation for primary or metastatic cancer in the lung in adults. This involves inserting a probe into the lung, through the skin of the chest, to send microwaves into the cancer cells. This produces heat, aiming to destroy the cancer (ablation).

    HealthTech guidance
    Published
    2 February 2022
    View recommendations

    Sections for HTG609

  5. Vaginal transluminal endoscopic hysterectomy and adnexal surgery for benign gynaecological conditions (HTG699)

    Evidence-based recommendations on vaginal transluminal endoscopic hysterectomy and adnexal surgery for benign gynaecological conditions. This involves removing the uterus (womb), and sometimes the fallopian tubes and ovaries, through the vagina.

    HealthTech guidance
    Published
    25 October 2023
    View recommendations

    Sections for HTG699

  6. Irreversible electroporation for treating liver metastases (HTG304)

    Evidence-based recommendations on irreversible electroporation for the treatment of liver metastases. This involves using very short electrical field pulses delivered over several minutes to destroy the tumour and a small surrounding tissue margin.

    HealthTech guidance
    Published
    23 February 2013
    View recommendations

    Sections for HTG304

  7. Cannabis-based medicinal products (NG144)

    This guideline covers prescribing of cannabis-based medicinal products for people with intractable nausea and vomiting, chronic pain, spasticity and severe treatment-resistant epilepsy.

    NICE guideline
    Last updated
    22 March 2021
    View recommendations

    Sections for NG144

  8. Intensity modulated radiotherapy for head and neck cancer [ID15]

    Discontinued Reference number: GID-TAG397

    Technology appraisal guidance
    Discontinued

  9. Prophylactic cranial irradiation compared with routine MRI follow-up in extensive-stage small-cell lung cancer: What is the effectiveness and cost effectiveness of prophylactic cranial irradiation compared with routine MRI follow-up in people with extensive-stage small-cell lung cancer without brain metastases?

    committee made the recommendation for research, see the rationale on thoracic radiotherapy and prophylactic cranial irradiation in SCLC...

    Research recommendation
    Published
    27 April 2023

  10. Cryotherapy for the treatment of liver metastases (HTG241)

    Evidence-based recommendations on cryotherapy for the treatment of liver metastases. This involves using cold temperatures applied through a special needle to destroy the cancer cells.

    HealthTech guidance
    Published
    15 December 2010
    View recommendations

    Sections for HTG241

  11. NICE encourages further research into preoperative high dose rate brachytherapy for rectal cancer. Trials should be designed to provide clear data on the efficacy of this procedure, whether or not other adjunctive treatments are used. Research should document adjunctive treatments and details of patient selection. Outcomes should include local recurrence, survival, disease-free survival and quality of life. NICE may update the guidance on publication of further evidence.

    boost to external beam radiotherapy. Evidence on the clinical efficacy of the procedure if used without external beam...

    Research recommendation
    Published
    12 October 2015

  12. Ambulight PDT for the treatment of non-melanoma skin cancer (HTG268)

    Evidence-based recommendations on Ambulight PDT for the treatment of non-melanoma skin cancer.

    HealthTech guidance
    Published
    25 July 2011
    View recommendations

    Sections for HTG268

  13. Risk of systemic anticancer treatment in people with cancer and COVID-19: Are patients with cancer and COVID-19 who are receiving/have recently received systemic anticancer treatment (SACT) (that is, within the 4 weeks preceding a diagnosis of COVID-19) at increased risk of severe COVID-19 illness or death?

    COVID-19 between people who have received SACT alone, radiotherapy alone, or both SACT and radiotherapy if there is a...

    Research recommendation
    Published
    21 October 2021

  14. Accessing NHS care and treatment recommended by NICE (ECD4)

    This document contains advice to help you access treatments and care that NICE has recommended

  15. Electrochemotherapy for primary basal cell carcinoma and primary squamous cell carcinoma (HTG333)

    Evidence-based recommendations on electrochemotherapy for primary basal cell carcinoma and primary squamous cell carcinoma. This involves injecting a chemotherapy drug into the tumour and using electrical pulses to increase its effect.

    HealthTech guidance
    Published
    26 February 2014
    View recommendations

    Sections for HTG333